Company intelligence / Profile preview

14ner Oncology

Boston, Massachusetts, United States

Ownership: Private
Employees: ~34
Development stage: Other

Overview

Elevation Oncology is a clinical-stage biotech company focused on developing antibody-drug conjugates targeting solid tumors with significant unmet medical need. Its lead candidate, EO-3021, is in Phase 1 trials as a monotherapy and in combinations for advanced gastric/gastroesophageal junction cancers, and it is also developing EO-1022 for HER3-expressing solid tumors.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugate
Industry: Biotech

Partnerships

CSPC Megalith Biopharmaceutical (China license agreement for EO-3021)

Beyond the preview

Go deeper on 14ner Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 14ner Oncology.

Explore the full profile